Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2005
08/04/2005US20050171123 Quinazoline derivatives as medicaments
08/04/2005US20050171122 Mitotic kinesin inhibitors
08/04/2005US20050171119 Two-layer tablet of efletirizine (2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid) containing an immediate release layer and a time-release layer for once daily dosage; antihistamine, bronchodilator and antispasmodic agent
08/04/2005US20050171118 Central nervous system, gastrointestinal and psycological disorders; such as 3-(4-chlorobenzenesulfonyl)-2-methyl-7-piperazin-1-yl-1H-indole; synthesis
08/04/2005US20050171117 Preparation of pharmaceutical salts
08/04/2005US20050171116 Vitamin E combined with one or more microbiocides selected from rifampicin, isoniazid, pyrazinamide and ethambutol, complexed with a reducing sugar; improved broad spectrum microbiocidal activity against drug resistant strains of mycobacterium, pseudomonas, escherichia, and staphylococcus
08/04/2005US20050171115 conditions ameliorated by monoamine reuptake; vasomotor symptoms; 4-[1-(3-chlorophenyl)-2-piperazin-1-ylethyl]tetrahydro-2H-pyran-4-ol; antidepressantp; sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome; nervous system disorders
08/04/2005US20050171114 Antitumor agents; superior cytotoxic activity; bioavailability; 1,2-dihydroxy-6-methoxy-3,3,14-trimethyl-1,2,3,14-tetrahydro-7H-benzo[b]-chromeno[6,5-g][1,8]naphthyridin-7-one; adenocarcinomas and carcinomas, sarcomas, gliomas and leukaemias; Derivatives of acronycine
08/04/2005US20050171113 Product comprising an inhibitor of the transduction of heterotrimeric G protein signals combined with an anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
08/04/2005US20050171112 treating nervous system diorders by administering inhibitors of glutaminyl cyclase and optionally inhibitors of propyl endopeptidases, dipeptidyl aminopeptidases, secretases, endopeptidase, angiotensin converting enzyme and neuropeptide Y receptor ligands, agonists or antagonists; enzyme inhibitors
08/04/2005US20050171111 E.g., 4-[[5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxymethyl]-1H-imidazol-1-yl]methyl]-benzonitrile; prevents the membrane attachment of p21ras and blocks the aberrant growth of ras-transformed tumors
08/04/2005US20050171110 Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one
08/04/2005US20050171107 Crystal forms of lamotrigine and processes for their preparations
08/04/2005US20050171106 5'-((benzo)thiophen-1 or 2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] compounds, optionally tritium labeled; binding ligands for nicotinic acetylcholine receptors
08/04/2005US20050171105 Methods and compositions as protein kinase inhibitors
08/04/2005US20050171104 Novel thyroid receptor ligands
08/04/2005US20050171103 Benzamide derivatives useful as histone deacetylase inhibitors
08/04/2005US20050171102 Semicarbazide derivatives for combating thromboembolic diseases
08/04/2005US20050171101 Neurodegenerative diseases; diseases ascribed by NMDA- and NO-induced neurotoxicity ; ischemia; antiinflammatory; anticancer; antidiabetic; 2-{3-[4-Phenyl-3,6-dihydro-1(2H)-pyridyl]propyl}-6(5H)-phenanthridinone
08/04/2005US20050171100 Dehydrative cyclization of a 3,7-dihydroxy-1,5-diazacyclooctane compounds; one pot process with milder reaction conditions
08/04/2005US20050171098 MCH antagonists and their use in the treatment of obesity
08/04/2005US20050171097 aryl is nitrogen heterocycyl; highly effective at a low dose and excellent in safety; farm and garden pests; 2-(2-propenylthio)-4-(4-trifluoromethylphenyl)benzonitrile
08/04/2005US20050171096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
08/04/2005US20050171095 Combination of CRF antagonists and 5-HT1B receptor antagonists
08/04/2005US20050171093 New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions
08/04/2005US20050171092 Chemical compounds
08/04/2005US20050171091 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
08/04/2005US20050171090 Use of vasopeptidase inhibitors in the treatment of metabolic diseases, nephropathy and advanced glycation end-product associated diseases
08/04/2005US20050171088 Quetiapine hemifumarate; well-tolerated antidepressant for bipolar disorders; side effect reduction of prolactin, sexual dysfunction and weight gain
08/04/2005US20050171087 high affinity agonists; high specificity; side effect reduction; endometriosis; hormone dependent cancers, fertility control; dibenzo[b,f]pyrido[1,2-d][1,4] oxazepin, dibenzo[b,f]pyrido[1,2-d][1,4]thiazepim, dibenzo[b,f]pyrido[1,2-d][1,4]diazepin and dibenzo[c,f]pyrido[1,2-a]azepine derivatives
08/04/2005US20050171086 Schizophrenia and depression concurrently; an atypical antipsychotic (Ziprasidone) with an aminomethylpyridyloxymethyl/ benzo[d]isoxazole-substituted pyrido[1,2-a]pyrazine as an antagonist to serotonin receptors D2, 5HT-2A and 5HT-1B; side effect reduction
08/04/2005US20050171085 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
08/04/2005US20050171084 Methods of treatment with lxr modulators
08/04/2005US20050171083 Modified release pharmaceutical formulation
08/04/2005US20050171080 Reacting 3-{2-[3-(fluorophenyl)-3-(trimethyl silyloxy)-propyl]-3-(4-fluoro phenyl amino)-3-(4-trimethyl silyloxy phenyl)-1-oxo-propyl}-4-(S)-phenyl oxazolidin-2-one with bis(trimethylsilyl)acetamide, quenching, adding sulfuric acid in an alcohol, isolating form I; pressurization of form I to form II
08/04/2005US20050171078 Cholinergic ligands at the nicotinic acetylcholine receptors; diseases related to the cholinergic system; neurodegenerative disorders; pain; antiinflammatory; diagnostic or monitoring tools using labelled forms; 3-Phenyletynyl-quinuclidin-2-ene
08/04/2005US20050171077 Compositions containing piperacillin and tazobactam
08/04/2005US20050171076 Targeted to specific tissues and/or disease states; target ATP binding sites; ruthenium and platinum with fused nitrogen heterocycle bidentate ligands and additional ligands that contact other parts of the active site, giving metal complex binders with high affinity and specificity; stablity; anticancer
08/04/2005US20050171075 Substitued 19-nor-cholestenes; antineoplastic agents, wound healing agents, antiinflammatory agents; autoimmune diseases, transplant rejection inhibition, hyperplasia, graft versus host disease; increased cell growth modulation and differentiation, low calcemic activity
08/04/2005US20050171074 3 alpha-hydroxy-3 beta-methoxymethyl-substituted steroids and the use thereof
08/04/2005US20050171073 An antiestrogen with an antiandrogen; Toremifene with Cyproterone; a SERM and a SARM; Prostate intraepithelial neoplasia, high-grade prostate intraepithelial neoplasia,benign prostate hyperplasia;
08/04/2005US20050171072 Therapeutic combinations and methods including IRM compounds
08/04/2005US20050171071 A kit containing 21 to 35 dosage units of an estrogen and a progestin in a non-ovulation inhibiting amount; fertility treatment
08/04/2005US20050171070 Stable salts of o-acetylsalicylic acid containing basic amino acids II
08/04/2005US20050171069 Methods and reagents for the treatment of multiple sclerosis
08/04/2005US20050171068 Novel 4-dedimethylaminotetracycline derivatives
08/04/2005US20050171067 Methods of treating disorders with group I mGluR antagonists
08/04/2005US20050171066 Vivo use of glutathione s-transferase activated nitric oxide donors
08/04/2005US20050171063 Plasmodium falciparum parasitic growth inhibition; such as phosphono formic or acetic acid
08/04/2005US20050171062 Administering to an animal having ocular hypertension or inflammatory bowel disease a piperidynly analog as for example 7-[2-oxo-6-((E)-3-oxo-oct-1-enyl)-piperidin-1-yl]-hept-5-ynoic acid methyl ester
08/04/2005US20050171061 Phenylsulfanylphenyl and phenyloxyphenyl substituted piperazine compounds; glycine transport inhibitors; for the treatment of psychoses and convulsive disorders: epilepsy, spasticity, and myoclonus
08/04/2005US20050171060 Anticancer agents and drug delivery agents with nucleotides
08/04/2005US20050171059 Silanol enzyme inhibitors
08/04/2005US20050171058 Method for preparing a glucosamine compounds and compound thus obtained
08/04/2005US20050171057 Pantoprazole cyclodextrin inclusion complexes
08/04/2005US20050171056 Sodium ion absorption inhibitors, and preventive and therapeutic agents and foods containing the same
08/04/2005US20050171055 Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
08/04/2005US20050171054 Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss
08/04/2005US20050171053 Producing zinc salt antimicrobial agents; precipitating lambda form in alcohol, soaking in metal salt, alcohol and water; separating complex, washing and drying
08/04/2005US20050171052 Solid, having improved handling characteristics; pourability
08/04/2005US20050171051 Pharmaceutical composition for diabetic neuropathy
08/04/2005US20050171050 Composition of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine
08/04/2005US20050171049 Compounds for the treatment of ischemia
08/04/2005US20050171048 Nuclease activity resistance; mixed sequence oligonucleotides containing purine or pyrimidine base in beta anomeric configuration; drug delivery agents; targeting specific DNA and/or RNA sequences
08/04/2005US20050171047 Immunostimulatory nucleic acid molecules
08/04/2005US20050171038 N-allyl-3-{2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide with HIV enzyme inhibitor
08/04/2005US20050171037 Therapeutic combinations
08/04/2005US20050171036 antitumor and anticarcinogenic agent; topoisomerase I inhibitor; synergistic effect by targeting different types of enzymes; low toxicity
08/04/2005US20050171034 5-methyl tetrahydrofolate and methylcobalamin with betaine, pyridoxal-5-phosphate and/or N-acetyl-cysteine; reducing metabolic waste levels
08/04/2005US20050171033 9N-substituted 6-11 bicyclic erythromycin derivatives
08/04/2005US20050171032 Methods for the treatment of cancer
08/04/2005US20050171031 Method and composition for the treatment of cancer
08/04/2005US20050171030 Relieving symptoms of erectile dysfunction and attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
08/04/2005US20050171029 polyphenols such as procyanidins; antitumor; inducing dephosphorylation of a hyperphosphorylated cell cycle regulatory protein in a tumor cell in which hyperphosphorylation/overexpression of said protein contributed to cell transformation
08/04/2005US20050171027 Compositions for treating or preventing obesity and insulin resistance disorders
08/04/2005US20050171026 Inhibiting SF2/ASF-dependent splicing of beta-globin pre-mRNA in vitro by suppression of Clk-mediated phosphorylation of SR proteins (serine/arginine-rich); a benzothiazole, TG003, is inhibitor of Clk/Sty(CDC2-like kinases); anticancer, antitumor; neurodegenerative diseases
08/04/2005US20050171025 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
08/04/2005US20050171024 Modulating angiogenesis
08/04/2005US20050171023 Apoptosis resistance; protecting healthy cells under environmental stress
08/04/2005US20050171022 Proteaseome inhibitors for the treatment of herpesviridae infected individuals
08/04/2005US20050171005 Inhibitors of beta-catenin Serine 45 (S45) phosphorylation e.g. Dishevelled (Dvl), a Wnt protein, phosphatase PP2A, and Casein kinase I (CKI) inhibitors; enhancers such as phosphatase inhibitor okadaic acid and protein that promotes beta-catenin acetylation, FRAT; drug screening; anticancer agents
08/04/2005US20050171002 Polyoxyalkylene compound and method for making
08/04/2005US20050170999 Excitatory amino acid receptor antagonists
08/04/2005US20050170509 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
08/04/2005US20050170504 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins
08/04/2005US20050170500 Methods for identifying risk of melanoma and treatments thereof
08/04/2005US20050170479 Method for producing lipids by liberation from biomass
08/04/2005US20050170444 Detecting levels of free placental growth factor in urine samples; enzyme-lined immunosorbent assay, fluorescence polarization assay, or a colorimetric assay
08/04/2005US20050170440 Treatment and diagnosis of insulin-resistant states
08/04/2005US20050170439 Using epidermal growth factor receptor complexes to diagnose and prognose health in cancer patients; drug screening; phosphatidyl inositol 3 kinase (pi3k)
08/04/2005US20050170438 Epidermal growth factors; ERBB/HER genes/proteins; electrophoresis; cancer biopsies
08/04/2005US20050170411 Genes and proteins involved in the biosynthesis of enediyne ring structures
08/04/2005US20050170394 GLUT1 transporters expressed in blood brain barrier cells
08/04/2005US20050170393 Using organic anion transporter polypeptide-related protein (OATPB) as diagnostic tool in detecting modulators for prevention and treatment of nervous system disorders
08/04/2005US20050170392 OAT3 transporters expressed in blood brain barrier cells
08/04/2005US20050170390 MCT1 transporters expressed in blood brain barrier cells
08/04/2005US20050170384 Expression vector comprising nucleotide sequences coding protein with sequence similarities to chordin proteins for use as tool in identifying modulator for treatment and prevention of infection and metabolic disorders
08/04/2005US20050170382 Immunoglobulin comprising receptor for advanced glycation endproducts for treating inflammation; antiinflammtory agents
08/04/2005US20050170364 Novel human kinase protein and polynucleotides encoding the same
08/04/2005US20050170355 Mixture of a nucleic acid and a chitosan with branching groups attached to the amino group, selected from alkyl groups with 2 or more carbon atoms, monosaccharides, oligosaccharides or polysaccharides; gene therapy, genetic vaccines, antisense therapy, anticarcinogenic agents, autoimmune diseases
1 ... 4591 4592 4593 4594 4595 4596 4597 4598 4599 4600 4601 4602 4603 4604 4605 4606 4607 4608 4609 4610 4611 ... 7860